Amicogen
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Amicogen makes specialist enzymes used in producing antibiotic ingredients, for example, the enzyme needed to manufacture the raw material at the heart of cephalosporin-class antibiotics, and has expanded into health-care ingredients such as collagen peptides and N-acetylglucosamine, as well as materials used in making antibody-based medicines.
Its customers include pharmaceutical manufacturers and biotech producers that rely on these inputs. Listed on KOSDAQ, Korea's tech and small-cap board, the company's business spans three areas: pharmaceutical enzymes, consumer health ingredients marketed under its own brand, and biopharmaceutical production materials.
Summary is AI-generated and may contain errors · figures from DART filings
Amicogen collaborates with Liechtenstein-based Lysando on commercialising endolysin enzymes, a next-generation antibiotic class targeting drug-resistant bacteria.
Amicogen in five facts
What does Amicogen do?
Amicogen makes specialist enzymes used in producing antibiotic ingredients, for example, the enzyme needed to manufacture the raw material at the heart of cephalosporin-class antibiotics, and has expanded into health-care ingredients such as collagen peptides and N-acetylglucosamine, as well as materials used in making antibody-based medicines.
Where is Amicogen listed and in which sector?
Amicogen (Korean name: 아미코젠) trades under KRX code 092040 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Consumer Staples sector, Food & Beverage.
How large is Amicogen?
Its market capitalisation was US$52.8M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Amicogen's latest annual revenue and operating profit?
For fiscal year 2025, Amicogen reported revenue of US$31.7M, an operating loss of US$12.9M and a net loss of US$22.9M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was down 75.8% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] Resolution to convene a general shareholders' meeting (extraordinary meeting)Oct 12
- [Amended] Shareholder register closure / record date setOct 12
- [Amended] Half-year report (2026.06)Oct 12
- DisclosureSep 28
- DisclosureSep 3
- Report on securities held by executives/major shareholdersSep 3
- [Amended] Resolution to convene a general shareholders' meeting (extraordinary meeting)Aug 31
- [Amended] Shareholder register closure / record date setAug 31
- [Amended] Agreement on change of control signed
Amicogen Co., Ltd. amends its June 29, 2026 disclosure of a change-of-control agreement, reporting that the agreement was terminated because the buyer failed to perform its contractual obligations; no transferor, transferee, subject matter, or price is now stated.
Ownership change · Aug 4 · 3 versions - [Amended] Material event report (rights offering)
Amicogen withdrew its June 22, 2026 third-party rights offering decision after the designated allottee, YK Bionova Holdings Co., Ltd., failed to pay the subscription funds.
Capital raise · Aug 4 · 5 versions - [Amended] Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Apr 28
- [Amended] Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Apr 28 · 2 versions
- [Amended] Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Apr 28 · 2 versions
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Amicogen reported consolidated results for FY2025: revenue of US$29.3M (−75.8% year on year), an operating loss of US$11.8M and a net loss of US$21M.
Earnings · Feb 27 - Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Feb 27
- Subscription results of rights offering or equity-linked bonds (voluntary)Capital raise · Feb 10
- Rights offering: final issue price setCapital raise · Feb 4
- [Amended] Material event report (rights offering)
Amicogen updated the terms of a public offering to raise US$20.7M, about 42.9% of its market value.
Capital raise · Feb 4 - [Amended] Material event report (rights offering)Capital raise · Jan 20